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Introduction: Currently, there is huge research focus on the development of novel cell-based regeneration and
tissue-engineering therapies for the treatment of intervertebral disc degeneration and the associated back pain.
Both bone marrow-derived (BM) mesenchymal stem cells (MSCs) and adipose-derived MSCs (AD-MSCs) are proposed
as suitable cells for such therapies. However, currently no consensus exists as to the optimum growth factor needed to
drive differentiation to a nucleus pulposus (NP)-like phenotype. The aim of this study was to investigate the effect of
growth differentiation factor-6 (GDF6), compared with other transforming growth factor (TGF) superfamily members,
on discogenic differentiation of MSCs, the matrix composition, and micromechanics of engineered NP tissue
constructs.
Methods: Patient-matched human AD-MSCs and BM-MSCs were seeded into type I collagen hydrogels and cultured
in differentiating media supplemented with TGF-β3, GDF5, or GDF6. After 14 days, quantitative polymerase chain
reaction analysis of chondrogenic and novel NP marker genes and sulfated glycosaminoglycan (sGAG) content of the
construct and media components were measured. Additionally, construct micromechanics were analyzed by using
scanning acoustic microscopy (SAM).
Results: GDF6 stimulation of BM-MSCs and AD-MSCs resulted in a significant increase in expression of novel NP marker
genes, a higher aggrecan-to-type II collagen gene expression ratio, and higher sGAG production compared with TGF-β
or GDF5 stimulation. These effects were greater in AD-MSCs than in BM-MSCs. Furthermore, the acoustic-wave speed
measured by using SAM, and therefore tissue stiffness, was lowest in GDF6-stiumlated AD-MSC constructs.
Conclusions: The data suggest that GDF6 stimulation of AD-MSCs induces differentiation to an NP-like phenotype and
results in a more proteoglycan-rich matrix. Micromechanical analysis shows that the GDF6-treated AD-MSCs have a
less-stiff matrix composition, suggesting that the growth factor is inducing a matrix that is more akin to the native
NP-like tissue. Thus, this cell and growth-factor combination may be the ideal choice for cell-based intervertebral disc
(IVD)-regeneration therapies.* Correspondence: judith.a.hoyland@manchester.ac.uk
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Low back pain (LBP), is an increasing socioeconomic bur-
den in today’s society. Current therapies involve con-
servative symptomatic pain relief or end-stage surgical
treatments. However, these therapies are relatively unsuc-
cessful in the long term and do not address the underlying
pathogenesis of LBP, such as IVD degeneration, which cor-
relates with LBP in 40% of cases [1].
Degenerative changes occur predominantly in the highly
hydrated central nucleus pulposus (NP) which is composed
of the proteoglycan, aggrecan, and type II collagen. With
degeneration, degradation of the extracellular matrix
(ECM) occurs, with substantial loss of aggrecan [2]. These
changes result in dehydration of the ECM, thereby influen-
cing tissue stiffness and strength, which leads to a reduction
in the structural integrity of the disc, ultimately comprom-
ising its function [3]. Given the poor long-term efficacy of
current clinical interventions, research is now focused on
cell-based tissue-engineering strategies. Such strategies aim
to target the underlying pathogenesis by replacing the cell
population and thereby restoring a functional IVD matrix.
Of these approaches, minimally invasive implantation of
mesenchymal stem cell (MSC)-seeded hydrogels offers the
most promise.
Both bone marrow- and adipose-derived MSCs (BM-
MSCs and AD-MSCs, respectively) are able to differentiate
into NP-like cells [4-6]. Native adult NP cells are conven-
tionally described as being ”chondrocyte-like” and charac-
terized through their rounded morphology and expression
of classic chondrogenic markers, including SOX-9, type II
collagen, and aggrecan [7]. However, the composition of
the NP and articular cartilage ECM is significantly different,
with NP tissue having a substantially more-proteoglycan-
rich ECM than has cartilage [8]. Thus, if MSCs are to be
used for IVD regeneration, it is essential to identify accu-
rately the differentiated cell phenotype and to ensure ap-
propriate ECM synthesis.
Our discovery of novel human NP cell markers (CAXII,
FOXF1, KRT 8, 18, 19) [9] has allowed a clear distinction to
be made between the chondrocyte and NP cell phenotype.
We previously demonstrated that these markers can be
used to identify accurately both BM-MSC and AD-MSC
differentiation toward NP-like cells [6]. This work used cul-
ture in a three-dimensional (3D) environment with media
containing TGF-β, a growth factor more commonly used
to induce chondrogenesis, and focused on gene and protein
marker expression by differentiated cells. However, al-
though such studies demonstrate that MSCs can be in-
duced to adopt an NP-like phenotype and hence synthesize
an ECM matrix that, in biochemical terms, is composition-
ally similar to native NP tissue, they provide no information
on the structural and biomechanical properties of the syn-
thesized matrix. Importantly, the mechanical behavior of
ECM-rich tissues is determined not only by the identity ofthe molecular components but also by their posttransla-
tional modification and assembly into structurally malleable
macromolecular aggregates [10-12]. Therefore, although
TGF-β has been commonly used by several groups to
induce NP-like differentiation, the effects of alternative
growth factors should be characterized with regard to cell
phenotype, protein synthesis, and crucially local stiffness to
optimize the biochemical and biomechanical characteristics
of the resultant construct.
Growth differentiation factor 5 (GDF5/BMP-14/CDMP-
1) and growth differentiation factor 6 (GDF6/BMP-13/
CDMP-2) are members of the TGF superfamily and are as-
sociated with skeletal development [13-15]. We previously
demonstrated that they are expressed by human NP cells
and that GDF5 increases type II collagen and aggrecan gene
expression by degenerate human NP cells in vitro [16].
GDF5 has also recently been shown to improve differenti-
ation of BM-MSCs to an NP-like phenotype (that is, disco-
genic differentiation) compared with TGF-β1, as shown by
the enhanced expression of the novel markers CAXII,
KRT19, and FOXF1 [17-19]. However, whereas differenti-
ation to NP-like cells was achieved, GDF5 did not produce
a more-proteoglycan (PG)-rich ECM than did TGF-β1. As
such, and given that GDF5 has also been shown to induce
chondrogenic differentiation [20], this may not be the opti-
mal growth factor for directing MSC differentiation to an
NP-like cell capable of synthesizing an ECM with appropri-
ate biochemical and biomechanical characteristics.
GDF6 has been shown to play an important role in spinal
column development, implying that it may have a pivotal
role in IVD development and homeostasis [21]. Further-
more, research has shown that injection of GDF6 prevents
IVD degeneration in an experimentally induced ovine
model [22]. Taken together, this suggests that GDF6 may
be an appropriate growth factor to drive MSC differen-
tiation toward an NP-like cell and hence to produce a PG-
rich ECM more akin to native IVD tissue than that pro-
duced by TGF-β- or GDF5-stimulated MSCs.
Thus, we hypothesized that the choice of exogenous
growth factor and MSC source would influence cell differ-
entiation, ECM composition, and mechanical stiffness of
engineered NP tissue constructs. Differentiation of both
BM-MSCs and AD-MSCs after stimulation with TGF-β,
GDF5, and GDF6 was assessed by expression of classic and
novel NP marker genes and PG production. Additionally,
by using scanning acoustic microscopy, the effect of ex-
ogenous growth factors on micromechanical stiffness of
tissue constructs was assessed, with acoustic wave speed
serving as a surrogate measure of tissue stiffness [23,24].
Methods
Mesenchymal stem cell culture
Human patient-matched AD-MSCs and BM-MSCs were
isolated from subcutaneous fat and bone marrow removed
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after approval from the North West Research Ethics
Committee and fully informed written consent of patients
(n = 7; average age, 47 years (age range, 22 to 78 years);
four women, three men). BM-MSCs were isolated and
expanded in α-MEM with 20% fetal calf serum (hereafter
termed standard media), as previously described [25].
After 5 days, nonadherent cells were discarded, and adhe-
rent cells were cultured to confluence.
To isolate AD-MSCs, adipose tissue was digested in
collagenase solution (30 mg collagenase type I in Hanks
Balanced Salt Solution (HBSS) and 20 mM calcium
chloride) for 2 hours at 37°C. The solution was filtered,
neutralized with standard media, and centrifuged for
5 minutes. Supernatant was aspirated, and cells cultured
to confluence in standard media, with nonadherent cells
discarded after 5 days.
The CD profile of BM-MSCs and AD-MSCs was ana-
lyzed by using flow cytometry and multipotentiality
assessed along the three mesenchymal lineages by using
standard methods (data not shown). Cells at passage 3
were used for subsequent experiments.
Encapsulation of MSCs in type I collagen hydrogels
Collagen gels were established by combining 3 mg/ml
atelosoluble type I collagen (Devro, Edinburgh, Scotland)
(pH 2), neutralization buffer (0.2M sodium phosphate, 1.3
M sodium chloride, pH 11.2) and αMEM at an 8:1:1 ratio,
respectively. MSCs were suspended in the collagen solution
at room temperature to a final cell density of 4 × 106/ml
and 100 μl gels formed in 0.4-μm high-density cell-culture
inserts (BD Biosciences, San Jose, CA, USA). Gels were cul-
tured for 24 hours in standard media, and media were sub-
sequently replaced with a differentiating medium, as
defined later, either with or without growth factor.
MSC pellet cultures
MSCs were dispensed into a 15-ml Falcon tube at a den-
sity of 250,000 cells in 2 ml of standard media. Sub-
sequently cells were centrifuged, incubated at 37°C for
24 hours, and media replaced with a differentiating media
either with or without the respective growth factor.
Differentiation of MSCs with TGF-β3, GDF5, and GDF6
MSCs were encapsulated in type I collagen gels and cul-
tured in differentiating media consisting of high-glucose
DMEM, 1% FCS, insulin-transferrin-selenium (ITS-X)
(Gibco, Grand Island, NY, USA), 100 μM ascorbic acid-2-
phosphate, 1.25 mg/ml bovine serum albumin (BSA), 10−7
M dexamethasone, 5.4 μg/ml linoleic acid, 40 μg/ml L-pro-
line, and 100 U/ml penicillin, 100 μg/ml streptomycin, and
2.5 μg/ml amphotericin B. To assess optimal growth-factor
concentration, media were further supplemented with
either no growth factor (control), TGF-β3 (Invitrogen) atconcentrations of 1, 10, 100 ng/ml, GDF5 (PeproTech,
Rocky Hill, NJ, United States) at concentrations of 10, 100,
or 1,000 ng/ml, or GDF6 (PeproTech) at concentrations of
10, 100, or 1,000 ng/ml for 14 days. Concentration ranges
were chosen to encompass manufacturers’ recommenda-
tions and previously published concentrations [18,26,27].
After this assessment, cells were encapsulated in type I
collagen gels or pellets and cultured in differentiating
media supplemented with either no growth factor or opti-
mal concentrations of growth factor for 14 days. Media
were changed every 48 hours and retained for subsequent
analysis of sulfated glycosaminoglycan (sGAG) content.
Assessment of NP marker gene expression with
quantitative real-time PCR
After 14 days, cell-seeded collagen hydrogels and pellets
were disrupted with Molecular Grinding Resin in TRIzol
(Geno Technology Inc., St. Louis, MO, USA), and RNA
was extracted according to the manufacturer’s recommen-
dations. cDNA was generated by using a high-capacity
cDNA reverse-transcription kit (Life Technologies) and
diluted to 5 ng/μl. Gene expression was analyzed with
quantitative real-time PCR by using an Applied Biosys-
tems StepOne Plus Real Time PCR system. Reactions
were prepared in triplicate by using LuminoCt qPCR
readymix reagents (Sigma-Aldrich, Irvine, UK) to a total
volume of 10 μl, containing 10 ng cDNA, 900 nM each
primer, and 250 nM probe. Data were analyzed according
to the 2-ΔΔ Ct method, with expression normalized to the
average of two prevalidated housekeeping genes (EIF2B1
andMRPL19) and to the control sample [28].
Assessment of PG sGAG content
sGAG production was assessed in triplicate by using a
dimethylmethylene blue (DMMB) assay, as previously
described [29,30], and quantified against a chondroitin
sulfate C (shark cartilage, Sigma) standard curve. Media
collected at each media change were also used to analyze
the PG content released into media on a cumulative
basis.
Total DNA content was measured by using a Quant-iT
PicoGreen assay (Life Technologies) with a lambda DNA
standard curve, according to manufacturer’s instructions.
sGAG values in gels/pellets were normalized to dsDNA
content.
Histologic characterization of ECM deposition
Collagen constructs were embedded in OCT; snap-frozen
in liquid nitrogen, and cryosectioned to a nominal thick-
ness of 5 μm. Safranin-O/Fast Green staining was per-
formed to localize sGAG according to standard protocols.
Picrosirius red staining and polarized light microscopy
were used to assess fibrillar collagen content, as previously
described [31]. Fibrillar collagen content was assessed by
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polarized light microscopy. Total tissue area was compared
with birefringent fibrillar collagen area, and percentage fi-
brillar collagen content calculated (these calculations were
based on overall intensity of staining and did not distin-
guish between color of staining, which subjectively shows
fibril diameter) [31]. Three areas were assessed per section,
from each of three sections per cell type and growth-factor
treatment.
Micromechanical characterization by scanning acoustic
microscopy
The SAM imaging technique has been described in detail
previously [11,24,32]. Imaging of hydrated cryosections
was performed by using a KSI 2000 microscope (PVA
TePla Analytical Systems GmbH; Herborn, Germany)
with bespoke data acquisition and control systems. SAM
data were collected in triplicate by using the Multi-Layer
Phase Analysis (MLPA) method [24] with a scan size of
200 μm and a frequency of 770 MHz to produce an acous-
tic wave speed map.
Statistical analysis
The nonparametric Mann–Whitney U test was applied
to determine significance to compare gene expression,
sGAG, and DNA. Values are reported as mean ± SEM.
Analysis of SAM data was conducted by using SPSS 20
(SPSS, Chicago, IL, USA). Q-q plots were used to test
for normality, and one-way ANOVAs were used to com-
pare means. For all analyses, a value of P < 0.05 was con-
sidered statistically significant.
Results
Optimal growth factor concentration
When compared with no growth factor controls, both
BM-MSCs (Figure 1A) and AD-MSCs (Figure 1B) de-
monstrated dose-dependent responses to all growth fac-
tors. Both COL2A1 and ACAN gene expressions were
significantly upregulated with all growth factors, whereas
novel maker gene expression was significantly upregu-
lated after GDF6 stimulation, in particular in AD-MSCs.
Overall, the optimal expression profiles were identified
at 10 ng/ml TGF-β and 100 ng/ml of GDF5 and GDF6.
Conventional NP marker expression in type I collagen
hydrogels
Culture of BM-MSCs in the presence of all growth fac-
tors (Figure 2A) resulted in a significant upregulation of
SOX9 and ACAN compared with the control, with the
largest upregulation of ACAN (13-fold) being identified
in the GDF6-stimulated cohort. Conversely, culture with
TGF-β demonstrated the greatest increase in expression
of COL2A1 (66-fold compared with control) compared
with treatment with either GDF5 (1.5-fold) or GDF6(2.5-fold). Culture of AD-MSCs in the presence of all
growth factors (Figure 2B) resulted in a significant in-
crease in ACAN expression compared with control, with
GDF6 again causing a significantly greater increase
(20-fold) than other growth-factor treatments. As with
BM-MSCs, TGF-β treatment of AD-MSCs resulted in the
largest upregulation of COL2A1 (34-fold) gene expression.
When the ACAN-to-COL2A1 relative gene expression
was assessed (2-ΔCtACAN-ΔCtCOL2A1), AD-MSCs stimulated
with GDF6 demonstrated the highest ratio of 75:1, whereas
BM-MSCs demonstrated a ratio of 29:1 (Figure 2C). Cells
treated with TGF-β demonstrated the lowest ratio overall
at 4:1 for AD-MSCs and 0.7:1 for BM-MSCs.
Novel NP marker expression in type I collagen hydrogels
Treatment of BM-MSCs with TGF-β and GDF5 caused
no change in KRT8, KRT19, or CAXII and a down-
regulation of KRT18, FOXF1, and T gene expression
compared with controls (Figure 2A). Conversely, treat-
ment with GDF6 significantly upregulated KRT8, 18, 19,
CAXII, and T, with no change noted in FOXF1 com-
pared with controls. Culture of AD-MSCs with GDF6
resulted in significant upregulation of all novel marker
genes compared with the control, and in the case of
KRT8, KRT18, KRT19, and T expression, was signifi-
cantly higher than that that seen in AD-MSCs cultured
with either TGF-β or GDF5 (Figure 2B). Comparison
between cell types showed that expression levels were
consistently upregulated to a greater extent in AD-
MSCs than in BM-MSCs.
SGAG content
AD-MSCs in type I collagen hydrogels showed significant
increases in the sGAG/DNA content within the con-
structs after stimulation with TGF-β (265.00 μg ±27.71)
and GDF6 (243.53 μg ± 13.87), whereas BM-MSCs dis-
played significant increases only after TGF-β stimulation
(215.59 μg ± 28.74) compared with controls (Figure 3A).
AD-MSCs consistently demonstrated higher levels of
sGAG/DNA compared with BM-MSCs, significantly so in
the case of GDF6 stimulation (149.60 μg ±17.05 in BM-
MSCs versus 243.53 μg ± 13.87 in AD-MSCs).
The sGAG released into the media over 14 days
(Figure 3B) was highest in AD-MSCs treated with GDF6
(103.69 μg ± 8.5 μg), although BM-MSCs and AD-MSCS
treated with either TGF-β or GDF6 consistently demon-
strated significant increases in released sGAG compared
with the control.
The combined total sGAG/DNA from both construct
and media showed that AD-MSCs treated with GDF6
produced the most sGAG (3,228.62 μg ± 185.98), and
this was significantly higher than the control group
(1,703.74 μg ± 72.89), or after treatment with either
TGF-β (2,414.88 μg ± 180.79) or GDF5 (2,512.97 μg ±
Figure 1 Quantitative real-time PCR analysis of gene expression in response to varying concentrations of growth factors. (A) BM-MSCs
and (B) AD-MSCs were seeded in type I collagen gels and stimulated with varying concentrations of TGF-β, GDF5, or GDF6 for 14 days. Relative
gene expression was normalized to mean housekeeping-gene expression and cells without growth-factor stimulation and plotted on a log scale.
N = 3; data represent mean ± SEM. *P < 0.05.
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after GDF-6 treatment (2,799.28 μg ±92.33), although this
was lower than that produced by AD-MSCs.Safranin-O staining of type I collagen hydrogels
(Figure 3D) demonstrated a more-widespread distri-
bution of sGAG within the GDF6-stimulated AD-MSC
Figure 2 Quantitative real-time PCR analysis of gene-expression changes in response to growth factor stimulation. (A) BM-MSCs, and (B)
AD-MSCs were cultured for 14 days in type I collagen hydrogels and stimulated with optimal concentrations of TGF-β, GDF5, or GDF6. Relative
gene expression was normalized to mean housekeeping-gene expression and cells without growth factor stimulation and plotted on a log scale.
(C) Aggrecan-to-type II collagen gene expression ratio in BM and AD-MSCs after culture in type I collagen hydrogels for 14 days with either no
growth factor, or optimal concentrations of TGF-β, GDF5, or GDF6. Relative gene expression was normalized to mean housekeeping-gene
expression and plotted on a log scale. N = 7; all data represent mean ± SEM. *P < 0.05.
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Figure 3 Analysis of sGAG production by BM and AD-MSCs in response to growth-factor stimulation. BM and AD-MSCs were seeded in
type I collagen hydrogels and cultured in the absence or presence of TGF-β, GDF5, or GDF6. (A) DMMB quantification of sGAG retained within gel
constructs, normalized to DNA content within the construct. (B) DMMB quantification of sGAG released cumulatively into the media throughout the
culture period. (C) Quantification of total sGAG content in the construct and media normalized to DNA content within the construct at day 14. N = 3,
data represent mean ± SEM. *P < 0.05. (D) Safranin O staining of MSC-seeded collagen gels demonstrating deposition of sGAG throughout the
constructs, with AD-MSCs stimulated with GDF6 having the highest and most homogeneous sGAG deposition. Scale bars, 500 μm.
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BM-MSCs treated with TGF-β showed staining confined
to the periphery of the construct only, whereas AD-MSCs
treated with either TGF-β or GDF6 demonstrated a more-
homogeneous distribution throughout the construct.
Fibrillar collagen content and local stiffness
Fibrillar collagen deposition by BM-MSCs was indepen-
dent of growth factor species (Figure 4; TGF-β, 15.4% ±
0.6%; GDF6, 16.0% ± 1.07%). In contrast, exposure to
exogenous TGF-β and GDF6 induced significant diffe-
rences in the deposition of fibrillar collagens by AD-MSCs
(Figure 4; TGF-β, 19.5% ± 0.9%; GDF6, 16.2% ± 0.7%).
These MSC source and growth factor-related differences
in fibrillar collagen content were, in turn, correlated withthe mean acoustic wave speed (and hence stiffness) of the
tissue constructs. Whereas mean acoustic wave speed in
TGF-β- and GDF6-treated BM-MSC constructs was
growth factor independent (Figure 5; TGF-β, 1,629 ms−1 ±
8 ms−1; GDF6, 1,642 ms−1 ± 17 ms−1), acoustic-wave speed
was significantly higher in TGF-β-treated AD-MSC seeded
constructs compared with their GDF6-treated coun-
terparts (Figure 5; TGF-β, 1,644 ms−1 ± 1 ms−1; GDF6,
1,599 ms−1 ± 4 ms−1).
MSC differentiation in pellet culture
To control for any influence of the reconstituted type I
collagen hydrogels on differentiation, MSCs were cultured
in three-dimensional pellets. Levels of conventional NP
marker-gene expression (Figure 6A, B) were similar to
Figure 4 Fibrillar collagen content visualized by using
polarized light microscopy of picrosirius red-stained sections.
(A) Picrosirius red staining of MSC-seeded type I collagen hydrogels
stimulated with TGF-β or GDF6, demonstrating enhanced fibrillar
collagen deposition (red and green stains) in AD-MSC-seeded
constructs stimulated with TGF-β compared with GDF6-stimulated
constructs. Scale bar, 500 μm. (B) Quantification of percentage fibrillar
collagen content in BM-MSC- and AD-MSC-seeded constructs after
stimulation with TGF-β or GDF6. AD-MSC-seeded constructs stimulated
with TGF-β demonstrated a significantly higher percentage of fibrillar
collagen content compared with GDF-6-stimulated constructs; N = 3.
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upregulation of ACAN after GDF6 stimulation, whereas
TGF-β induced the largest increase in COL2A1 expression
in both cell types. BM-MSCs demonstrated either no
change or a downregulation of novel NP marker genes
after TGF-β or GDF5 stimulation, with GDF6 causing
significant upregulation of KRTs 8, 18, and 19, FOXF1,
CAXII, and T (as with type I collagen hydrogels). In AD-
MSCs, GDF6 caused a significant upregulation of all
marker genes, with increases in KRT8, 18, 19, CAXII, and
T being significantly higher after GDF6 stimulation than
with either TGF-β or GDF5.The ratio of ACAN-to-COL2A1 in BM-MSCs and AD-
MSCs was higher in both GDF5 and GDF6 groups com-
pared with either controls or TGF-β-treated cells, with
no significant difference identified between the two cell
types after stimulation with any of the growth factors
(Figure 6C).
Total GAG/DNA from both pellets and accumula-
ted media showed that AD-MSCs treated with GDF6
had the highest total value (3,556.31 μg ± 133.06), and
this was significantly higher than both the control
(2,206.34 μg ± 267.54), and after treatment with either
TGF-β (2,540.32 μg ± 32.78) or GDF5 (2,886.65 μg ±
225.76) (Figure 6D).
Discussion
Given the similarities in gene-expression profiles between
articular chondrocytes and NP cells, specifically expres-
sion of SOX-9, type II collagen, and aggrecan, researchers
have increasingly investigated the potential of MSCs to re-
generate the IVD. However, to date, studies have applied
methods more commonly used to induce chondrogenesis,
specifically, culture in a 3D environment and differentia-
ting media containing TGF-β and thereafter using ECM
gene and protein expression as outcome measures to de-
pict an NP-like tissue.
However, the differences in matrix composition bet-
ween articular cartilage and NP tissue, together with re-
cent phenotypic profiling studies comparing their native
cells, suggest that these outcome measures are insuffi-
cient to define the end-stage differentiated cell and that
more-detailed analyses are needed. Given the increased
understanding of the NP cell phenotype, unique phe-
notypic markers can now be used to define accurately
the lineage-specific MSC differentiation toward NP-like
cells. This has allowed alternative culture systems, in
particular, comparison of different growth factors, to be
investigated with the aim of optimizing MSC discogenic
differentiation and ensuring synthesis of an ECM with
appropriate biochemical and biomechanical properties.
Members of the TGF-β superfamily are potential can-
didates for driving discogenic differentiation, with a re-
cent study showing that GDF5 induces differentiation of
MSCs in vitro to a more-IVD-like phenotype than TGF-β
[17-19]. Given that we previously demonstrated expres-
sion of GDF5 and GDF6 by human NP cells [16] and that
both AD-MSCs and BM-MSCs can differentiate to NP-
like cells [6], here we aimed to investigate whether GDF6
may be a more-appropriate stimulus for MSC discogenic
differentiation and production of an NP-like ECM than
either TGF-β or GDF5.
Stimulation of both AD-MSCs and BM-MSCs with
GDF6 resulted in increased expression of novel NP phe-
notypic marker genes KRT8, 18, and 19, FOXF1 and
CAXII, compared with either TGF-β or GDF5, particularly
Figure 5 Mean acoustic wave speed (a surrogate measure of tissue stiffness) assessed with scanning acoustic microscopy. (A) Acoustic
wave-speed distribution maps of BM-MSC- and AD-MSC-seeded type I collagen hydrogels stimulated with TGF-β or GDF6. Scale bar, 50 μm.
(B) Quantification of wave speed in BM-MSC- and AD-MSC-seeded constructs after stimulation with TGF-β or GDF6. GDF6 stimulation of AD-MSCs
resulted in a significantly decreased acoustic-wave speed compared with TGF-β-stimulated constructs, suggesting that GDF6-stimulated AD-MSC
produced a less-stiff ECM. N = 3. *P < 0.05. (C) Wave-speed distribution in AD-MSC-seeded constructs after stimulation with either TGF-β or GDF6.
The GDF6-stimulated construct shows significantly reduced mean wave speed of 1,599 ms−1 compared with the TGF-β-stimulated
counterpart, 1,644 ms−1.
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identified as NP specific and previously used to depict ap-
propriate differentiation [6,9] , the observed increases in
gene expression suggest that both AD-MSCs are BM-
MSCs are capable of discogenic differentiation, which is
particularly enhanced by GDF6.
We also investigated the expression of the notochordal
and mesodermal marker brachyury (T), which has pre-
viously been shown to be expressed by adult NP cells [9]
and demonstrated the greatest induction of gene expres-
sion after GDF6 stimulation, again particularly in AD-
MSCs. Importantly, these findings were consistent with
both cell types in both type I collagen hydrogel and
pellet cultures, suggesting that the biomaterial did notinfluence differentiation, with growth-factor choice having
the predominant effect on discogenic differentiation.
The molecules aggrecan and type II collagen are key
components of the IVD ECM, with a higher aggrecan-
to-type II collagen ratio (both at the gene transcription
[17] and protein [8] level being indicative of an NP-like,
rather than articular cartilage-like phenotype/matrix). As
expected [32,33], stimulation of both BM-MSCs and
AD-MSCs with TGF-β resulted in the highest COL2A1
gene expression and lowest ACAN-to-COL2A1 ratio.
When combined with the decrease or small upregulation
of novel NP marker genes in BM-MSCs and AD-MSCS,
respectively, and the increased expression of SOX-9
(major transcription factor for chondrogenesis), the data
Figure 6 (See legend on next page.)
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Figure 6 Analysis of BM and AD-MSC response to growth-factor stimulation in pellet culture. Quantitative real-time PCR analysis of
gene-expression changes in (A), BM-MSCs and (B), AD-MSCs in pellets in the absence or presence of TGF-β, GDF5, or GDF6. Relative gene
expression was normalized to mean housekeeping-gene expression and cells without growth-factor stimulation and plotted on a log scale.
(C) Aggrecan-to-type II collagen gene-expression ratio in BM and AD-MSCs after culture in type I collagen hydrogels for 14 days with either no
growth factor, TGF-β, GDF5, or GDF6. Relative gene expression was normalized to mean housekeeping-gene expression and plotted on a log
scale. (D) DMMB quantification of sGAG content within pellets and cumulative release into media over 14 days normalized to DNA content of the
pellet at day 14. For all analyses, N = 3; data represent mean ± SEM. *P < 0.05.
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a chondrocyte-like phenotype. Conversely, as was pre-
viously reported, GDF5 promoted ACAN gene expression,
and resulted in an increased ACAN-to-COL2A1 ratio
compared with TGF-β stimulation [17,18]. Although
stimulation of BM-MSCs with GDF6 resulted in a similar
response to that of GDF5, AD-MSCs stimulated with
GDF6 produced significantly higher levels of ACAN
and demonstrated the highest ACAN-to-COL2A1 ratio,
indicative of an NP-like phenotype. Importantly, this
gene-expression analysis (as assessed by using both
conventional and novel NP markers, as well as ACAN-
to-COL2A1 ratio) has shown that GDF6 promotes dis-
cogenic differentiation of both BM-MSCs and AD-MSCs,
with gene-expression changes being greatest in AD-MSCs,
suggesting that these cells may be more able to differen-
tiate to an NP-like phenotype.
Further to characterize these differences between the
differentiated cell populations and to ensure that changes
in gene expression were reflected at the protein level,
analysis of sGAG synthesis was assessed. Cells under all
conditions synthesized detectable levels of sGAG, with
significant increases in retained sGAG (normalized to
DNA) seen after TGF-β stimulation in both BM-MSCs
and AD-MSCs, and after both TGF-β and GDF6 stimu-
lation in AD-MSCs. A substantial amount of sGAG was
also released into the media by all cells, with significant
increases again being seen in both cell types after stimula-
tion with either TGF-β or GDF6. Whereas the majority of
newly synthesized sGAG was not retained within the
constructs, similar findings have been observed in other
comparable studies [19,34]. This may be due to the fiber
density of the matrix produced, with differences in col-
lagen synthesis or remodeling of the collagen hydrogel al-
tering matrix retention.
However, when total sGAG synthesis was analyzed and
normalized to DNA content, significantly more sGAG was
synthesized by AD-MSCs after stimulation with all three
growth factors, with AD-MSCs stimulated with GDF6 pro-
ducing the most sGAG. Interestingly, GDF5 did not result
in significant increases in sGAG synthesis in either cell
type, a finding that has been reported for BM-MSCs pre-
viously [18]. As with the gene-expression profile, DMMB
analysis revealed similar results after pellet culture, with
GDF6-stimulated BM- and AD-MSCs synthesizing thelargest amount of sGAGs. Interestingly, safranin-O staining
of the collagen constructs also highlighted differences,
whereas AD-MSCs stimulated with either TGF-β or GDF6
demonstrated more-intense safranin O staining than BM-
MSCs, supporting the DMMB analysis on retained sGAG.
Additionally, a homogeneous GAG distribution was
observed throughout the construct compared with the
more-focal/discrete staining in BM-MSC constructs.
Overall, given that GDF6-stimulated AD-MSCs produce
the highest levels of sGAG and the most homogeneous
matrix deposition, this cell type and stimulation may be
the more-appropriate choice for regeneration of the
PG-rich NP, whereas TGF-β may promote a more-
articular cartilage-like matrix.
Although the majority of studies to date have relied on
molecular and biochemical methods to characterize the
ability of tissue-construct systems to mimic the target
tissues, the micro- and hence macromechanical behavior
of the construct is likely to influence the efficacy of any
resulting therapy. Therefore, in this study, we quantified
the acoustic-wave speed [23] of tissue-construct cryo-
sections (which is proportional to the square root of the
material’s Young modulus (stiffness)) [35]. Having pre-
viously used SAM to localize age-related changes in vas-
cular stiffness [24], here we demonstrate that a refined
version of this technique (MLPA) is able to distinguish
cell- and cytokine-specific effects on the resultant micro-
mechanical behavior of tissue constructs. Furthermore,
these effects are in concordance with our other findings
that AD-MSC-seeded constructs treated with GDF6
showed decreased fibrillar collagen and increased pro-
teoglycan deposition when compared with their TGF-β-
treated counterparts.
AD-MSCs are thought to be better candidates for cell
therapy because of their ease of access, limited donor-site
morbidity, and high proliferation rate. Importantly, this
study demonstrated differences in regenerative potential
for IVD application between BM-MSCs and AD-MSCs,
with the data suggesting that AD-MSCs are more able to
undergo discogenic differentiation and produce an ap-
propriate PG-like matrix. It was previously reported that
AD-MSCs have a reduced capacity to differentiate to a
chondrogenic lineage compared with BM-MSCs [36] be-
cause of differences in receptor expression (specifically,
TGF-β receptor I [36]) compared with BM-MSCS. As
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tors used here (with TGF-β stimulating more of a chon-
drogenic phenotype and GDF-6, an NP- like phenotype
and matrix) may be due to differences in cell-signaling
pathways despite all being members of the TGF-β super-
family. TGF-β3 is recognized by type II (TGFRII) and type
I surface receptors (ALK5, ALK1), which in turn facilitate
the Smad 2/3 signaling pathway.
Conversely, GDF5 and GDF6 use BMPRII, ActRIIa,
ALK3, and ALK6 receptors activating the alternative
Smad 1/5/8 pathway [37]. Activation of these distinct sig-
naling pathways may then lead to different downstream
signals, which may explain the more-chondrogenic nature
of TGF-β3 stimulation. GDF5 and GDF6 are 82% homolo-
gous in the highly conserved active C-terminal (mature
signaling) domain [38] and are thus likely to operate
by similar ligand/receptor interactions. However, recent
evidence reporting differential effects of these factors on
mouse calvarial osteogenesis [39] would suggest that these
growth factors may have distinct signaling effects, despite
similar receptor use, which could also account for the dif-
ferential effects seen here, although elucidation of the sig-
naling mechanisms is beyond the scope of this article.
Conclusion
The phenotype of differentiated cells, together with
the ECM composition and micromechanics of tissue-
engineered constructs, must be extensively characterized
to ascertain that an appropriately functioning tissue is
formed. In this study, we demonstrated differentiation of
MSCs to an NP-like phenotype and formation of appro-
priate NP ECM components. Interestingly, AD-MSCs
treated with GDF6 produced a less-stiff, PG-rich matrix,
which may be more indicative of the native healthy NP
ECM.
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